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Management of ischemic nephropathy:
Dialysis-free survival after surgical repair
Kimberley J. Hansen, MD, Gregory S. Cherr, MD, Timothy E. Craven,
MSPH, Stephen J. Motew, MD, Jeffrey A. Travis, MD, James M. Wong, MD,
Pavel J. Levy, MD, Barry I. Freedman, MD, John Ligush, Jr, MD, and
Richard H. Dean, MD, Winston-Salem, NC
Purpose: This retrospective review describes the surgical management of consecutive
patients with severe hypertension and ischemic nephropathy due to atherosclerotic
renovascular disease.
Methods: From January 1987 through December 1998, a total of 590 patients under-
went operative renal artery repair at our center. A subgroup of 232 hypertensive patients
(97 women, 135 men; mean age, 66 ± 8 years) with atherosclerotic renovascular disease
and preoperative serum creatinine levels of 1.8 mg/dL or more forms the basis of this
report. Change in renal function was determined from glomerular filtration rates esti-
mated from preoperative and postoperative serum creatinine. The influence of selected
preoperative parameters and renal function response on time to dialysis and dialysis-free
survival was determined by a proportional hazards regression model.
Results: In all, 83 patients underwent unilateral renal artery repair and 149 patients
underwent bilateral repair, including repair to a solitary kidney in 17 cases. A total of
332 renal arteries were reconstructed, and 32 nephrectomies were performed in these
patients. After surgery, there were 17 deaths (7.3%) in the hospital or within 30 days of
surgery. Advanced patient age (P = .001; hazard ratio, 1.1; 95% CI [1.1, 1.2]) and con-
gestive heart failure (P = .04; hazard ratio, 2.9 CI [1.0, 8.6]) demonstrated significant
and independent associations with perioperative mortality. With a change of 20% or
more in EGFR being considered significant, 58% of patients had improved renal func-
tion, including 27 patients removed from dialysis dependence; function was unchanged
in 35% and worsened in 7%. Follow-up death from all causes or progression to dialysis
dependence demonstrated a significant and independent association with early renal
function response. Both patients whose function was unchanged (P = .005; hazard ratio,
6.0; CI [2.2, 16.6]) and patients whose function was worsened (P = .03; hazard ratio,
2.2; CI [1.1, 4.5]) remained at increased risk of death or dialysis dependence. For
patients with unchanged renal function after operation, risk of death or dialysis demon-
strated a significant interaction with preoperative renal function. In addition to severe
preoperative renal dysfunction, diabetes mellitus demonstrated a significant and inde-
pendent association with follow-up death or dialysis.
Conclusion: Surgical correction of atherosclerotic renovascular disease can retrieve excre-
tory renal function in selected hypertensive patients with ischemic nephropathy. Patients
with improved renal function had a significant and independent increase in dialysis-free
survival in comparison with patients whose function was unchanged and patients whose
function was worsened after operation. These results add further evidence in support of
a prospective, randomized trial designed to define the value of renal artery intervention
in patients with ischemic nephropathy. (J Vasc Surg 2000;32:472-82.)
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Historically, the evaluation and management of
atherosclerotic renal artery disease focused on the
presence and treatment of associated hypertension.
In recent years, however, the relationship between
renal artery disease and excretory renal insufficiency
(ie, ischemic nephropathy) has received increased
attention as an important cause of progressive renal
failure.1,2 Despite this recognized relationship,
enthusiasm for treatment of ischemic nephropathy
varies widely. In some instances, authors caution
against renal artery intervention for ischemic
nephropathy, citing uncertain renal function
response in a patient population characterized by
diffuse extrarenal atherosclerosis and limited long-
term survival.3-6 Conversely, others have recom-
mended intervention for asymptomatic renal artery
lesions (ie, without hypertension or renal insuffi-
ciency), fearing inevitable and irretrievable loss of
renal function.7-10
In addition to these controversies, opinions
regarding the preferred method of renal artery inter-
vention are equally diverse. Proponents of percuta-
neous transluminal balloon angioplasty (PTA) and
proponents of surgical repair cite selected clinical
series to support their respective views. Unfortunately,
data pertaining to the primary goals of both PTA and
surgery—increased renal function and improved 
dialysis-free survival—are incomplete for ischemic
nephropathy.1,5,11,12 Consequently, management
choices often emphasize perceived differences in mor-
bidity and stress immediate technical results rather
than long-term outcome.
This retrospective review of a single center’s
cumulative experience with atherosclerotic renal
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artery disease describes the operative management
of consecutive hypertensive patients with ischemic
nephropathy. In addition to the immediate blood
pressure and renal function response after operation,
specific points of interest included (1) preoperative
predictors of dialysis-free survival and (2) the effect
of blood pressure and renal function response on
eventual dialysis dependence and dialysis-free sur-
vival.
PATIENTS AND METHODS
Patient population. From January 1987
through December 1998, a total of 590 patients
underwent surgical repair of renal artery disease at
the authors’ center. After removal from high-dose
diuretics, converting enzyme inhibitors, and
angiotensin receptor antagonists, each of 232
patients with atherosclerotic renovascular disease
had a preoperative serum creatinine (SCr) level of
1.8 mg/dL or more; included were 38 patients
dependent on dialysis. These 232 patients were con-
sidered to have ischemic nephropathy, and they con-
Fig 1. Graphic depiction of interaction between graded
renal function response to operation, preoperative EGFR,
and effect on follow-up death or dialysis dependence
among patients with ischemic nephropathy. Curves show
estimated hazard ratio for patients with “no change” vs
“improved” function (solid curve) and associated upper
and lower 95% confidence limits (broken curve) for values
of preoperative EGFR, ranging from 5 to 35
mL/min/m2. Horizontal line at 1.0 denotes value of no
association. 95% CI for hazard ratio includes 1.0 for pre-
operative EGFR more than 23 mL/min/m2.
Table I. Prevalence of extrarenal atherosclerosis in
patients with ischemic nephropathy (n = 232
patients)
Extrarenal ASO No. of patients (%) Clinical finding (%)
Cardiac 158 (68) MI 79
CHF 72
LVH 124
Cerebrovascular 70 (32) TIA 27
CVA 36
CEA 38
Aortoiliac 138 (60) AAA 57
CSOD 108
At least 1 clinical 202 (87)
finding
AAA, Abdominal aortic aneurysm; ASO, atherosclerosis; CEA,
carotid endarterectomy; CHF, congestive heart failure; CSOD,
clinically severe occlusive disease; CVA, cerebrovascular accident;
LVH, left ventricular hypertrophy; MI, myocardial infarction;
TIA, transient ischemic attack.
stitute the basis of this report. This subgroup includ-
ed 97 women and 135 men ranging in age from 30
to 86 years (mean, 66 ± 8 years).
Severe hypertension was present in each patient
(mean blood pressure, 204 ± 34/106 ± 21 mm Hg;
mean number of medications, 2.8 ± 1.1) and ranged
in duration from 9 to 57 years (mean, 11 years). In
addition to severe hypertension in combination with
excretory renal insufficiency, extrarenal atherosclerosis
was evidenced by cardiac disease (68%), cerebral vas-
cular disease (32%), and aortoiliac disease (60%). Only
30 patients (13%) were free of clinical extrarenal ath-
erosclerosis (Table I). In addition, type 2 diabetes had
been diagnosed in 35 patients (15%) with 3 to 22
years (mean, 12.2 years) before operation.
Patient evaluation. After physical examination,
electrocardiography, and the taking of a complete
medical history, 197 patients underwent further car-
diac evaluation. These evaluations included resting
and/or stress echocardiography (191 patients), stress
electrocardiography (12 patients), and cardiac
catheterization (28 patients) and resulted in 15 coro-
nary interventions (11 percutaneous transluminal
coronary angioplasties and 4 coronary artery bypass
grafts) preliminary to renal artery repair.
Cut-film angiography demonstrated significant
unilateral renal artery disease (≥ 80% orificial steno-
sis or occlusion) in 83 patients and bilateral disease
in 149 patients, including 17 patients each having
significant disease to a solitary kidney. In all, 116
complete renal artery occlusions were observed in
109 patients. Concomitant severe aortic occlusive
disease, including 21 aortic occlusions, was found in
108 patients, and a significant abdominal aortic
aneurysm was demonstrated in 57 patients.
Fifty-one patients with hypertension under satis-
factory medical control who demonstrated unilateral
renovascular disease were studied with renal vein
renin assays or split renal function tests. Lateralization
was observed in 29 patients. Isotopic renography was
performed in 57 patients before surgical repair. Forty-
three kidneys with significant renal artery disease sup-
plied less than 10% to 20% of total renal function.
Operative management. Renal artery recon-
struction was performed in every instance of signifi-
cant renal artery disease when a normal distal renal
artery could be demonstrated at surgery. Primary
nephrectomy was reserved for an unreconstructable
renal artery to a kidney providing less than 10% to
20% of total renal function by preoperative renogra-
phy. Eighty-three patients underwent unilateral
renal artery repair; 122 patients had bilateral repair,
including 17 patients each having a solitary kidney;
and 27 patients had unilateral repair with contralat-
eral nephrectomy. Direct aortorenal reconstruction
to 328 kidneys included aortorenal bypass (210
instances), thromboendarterectomy (103 instances),
and reimplantation (15 instances). A splanchnorenal
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Fig 2. A, Product-limit estimates of all-cause mortality for patients with ischemic nephropathy as a
function of hypertension response to operation. B, Product-limit estimates of cardiovascular or renal
mortality for patients with ischemic nephropathy as a function of hypertension response to operation.
Hypertension response did not affect rate of death or of cardiovascular death.
A B
bypass graft was performed in four instances.
Combined aortic reconstruction was performed in
87 patients (37%). Thirty patients underwent repair
of clinically significant aortic occlusive disease, and
57 patients underwent simultaneous repair for
abdominal aortic aneurysm.
Statistical methods and analysis. To account
for between-subject differences in sex, age, and
weight, we transferred all values of SCr to a calculat-
ed measure of estimated glomerular filtration rate
(EGFR, mL/min/1.73 m2) through use of the for-
mula of Cockroft and Gault, modified by Rolin et
al,13 as follows: 
EGFR = (140 – age)(weight) × 1.73
(72)(SCr) BSA,
where BSA is the body surface area. BSA was calcu-
lated through use of the following formula: BSA =
[height (cm)].725 × [weight (kg)].425 × .007184.
For female subjects, the EGFR was multiplied by
0.85 to correct for sex-related differences in muscle
mass and average rate of creatinine synthesis.
Descriptive statistics for factors of interest were
computed for patients with ischemic nephropathy
(SCr levels of ≥ 1.8 mg/dL). Changes in EGFR ver-
sus site of disease were assessed through use of
unpaired t tests to test between-group differences in
preoperative levels, paired t tests to assess for preoper-
ative to postoperative within-group changes, and
analysis of covariance (controlling for preoperative
EGFR) to test for between-group differences in post-
operative levels. Three long-term follow-up outcomes
were examined: (1) survival time, (2) dialysis-free
time, and (3) dialysis-free survival (ie, time to death or
dialysis, whichever occurred first). These outcomes
were depicted graphically through use of Kaplan-
Meier product-limit estimates.14 In the group with
SCr levels of 1.8 mg/dL or more, examination of the
effect of renal function response to operation on each
outcome was assessed through use of multivariable
Cox proportional hazards models.15 Separate “best”
models were selected for each outcome through use
of a backward stepwise elimination technique where-
by all factors of interest were included in the first step
and factors not significant at the .10 α-level were
eliminated one by one until all factors remaining in
the model were significant at the .10 level.15
RESULTS
Postoperative morbidity and mortality
Early events. There were 17 patient deaths
(7.3%) in the hospital or within 30 days of surgery.
Data on these perioperative deaths are summarized
in Table II. All but one of the deaths occurred after
bilateral renal artery reconstruction or unilateral
reconstruction combined with simultaneous aortic
repair. Perioperative mortality demonstrated signifi-
cant and independent associations with advanced
patient age (P = .001; hazard ratio, 1.1; 95% CI
[1.1, 1.2]) and preoperative congestive heart failure
(P = .04; hazard ratio, 2.9, 95% CI [1.1, 8.6]).
Perioperative morbidity contributing to periopera-
tive death or prolonged hospitalization occurred in 70
patients (30%). These events included myocardial
infarction (14 patients), cerebrovascular accident (7
patients), and significant arrhythmia (20 patients). In
addition, 17 patients required more than 5 days of
mechanical ventilatory support, and 20 patients were
treated for pneumonia. Twenty-one patients demon-
strated an increase in SCr, which resolved sponta-
neously in 17 instances and required permanent dialy-
sis in four instances. Among the four patients in whom
dialysis was initiated within 1 month of surgery, mean
preoperative SCr and EGFR values were 3.8 mg/dL
and 17.1 mL/min · m2, respectively.
A total of 580 intraoperative and postoperative
renal duplex sonography scanning examinations
were performed on follow-up. Overall, intraopera-
tive revision of major B-scan defects were required in
12% of repairs. Each of 185 patients had at least one
postrepair study, for a total of 276 renal artery
reconstructions.
Late events. Follow-up data (mean, 38.3
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Fig 3. Product-limit estimates of time to death or dialysis
for patients with ischemic nephropathy according to renal
function response after operation.
months; range, 0.3-146.6 months) were available
for 99% of surgical survivors. During follow-up,
there were 72 additional deaths among the athero-
sclerotic patients with ischemic nephropathy.
Cardiovascular events accounted for most (41%) of
these late deaths, including myocardial infarction
(22%) and cerebral vascular accident (6%).
Noncardiovascular causes, including malignancies,
accounted for 15% of the deaths. End-stage renal
disease contributed to 22% of late deaths. Cause of
death was unknown in 21% of cases.
Forty-one patients progressed to eventual dialy-
sis dependence. Of these 41 patients, 24 (59%) died
on follow-up. The median survival time for patients
reaching dialysis dependence was 15.9 months. By
product-limit estimates, the survival among this
group was 20% at 5 years. In all, postoperative renal
duplex sonography scanning demonstrated that five
renal artery reconstructions developed recurrent
stenosis (2%) on follow-up. Recurrent stenosis did
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not occur in patients with worsened postoperative
renal function. Specifically, no patient progressing to
dialysis dependence had anatomic failure of renal
artery repair (defined by means of renal duplex scan-
ning).
Table III summarizes the proportional hazard
regression analysis for time to dialysis or death from
all causes during follow-up. Significant and indepen-
dent associations were observed for (1) preoperative
renal function and diabetes mellitus and (2) postop-
erative renal function both unchanged and worsened
in comparison with renal function improved after
surgery. A significant interaction between preopera-
tive EGFR and risk of death or dialysis was observed
among patients with unchanged renal function when
preoperative EGFR fell below 23 mL/min · m2
(Fig 1).
Blood pressure response
Blood pressure response was determined from
Table II. Summary of perioperative deaths (n = 17 patients) 
Sex/age (y) Preoperative SCR*/EGFR† Operation Cause of death
Female/79 3.7/11.9 BILAT-RAB MSOF
Male/70 3.1/24.5 BILAT-TEA/AAA Pulmonary failure
Female/64 3.1/15.9 R-TEA and L-NEPH Sepsis
Female/69 1.8/31.9 BILAT-TEA CVA
Male/71 2.2/29.5 BILAT-RAB MI
Female/63 2.0/30.6 L-RAB (SOL) CVA
Female/71 12.0/4.6 BILAT-RAB Hepatic failure
Male/78 4.1/13.7 REIMP and L-NEPH MSOF
Female/69 1.9/28.8 L-RAB and R-NEPH/AAA CVA
Male/73 12.0/4.4 L-TEA/AFBG ESRD
Female/79 2.7/21.0 BILAT-RAB MSOF
Female/69 2.3/21.9 BILAT-RAB/AAA Hepatic failure
Female/74 1.8/29.5 L-RAB Sepsis
Female/74 2.3/18.0 R-RAB/AAA MI
Male/78 1.8/27.3 BILAT-TEA MSOF
Male/78 2.8/21.3 BILAT-RAB/AAA Sepsis
Female/65 2.6/21.9 L-RAB/AFBG Hepatic failure
*In mg/dL.
†In mL/min · m2.
AAA, Abdominal aortic aneurysm; AFBG, aortobifemoral bypass graft; BILAT, bilateral; CVA, cerebrovascular accident; ESRD, end-
stage renal disease; MI, myocardial infarction; MSOF, multisystem organ failure; NEPH, nephrectomy; RAB, renal artery bypass;
REIMP, reimplantation; SOL, solitary kidney; TEA, thromboendarterectomy.
Table III. Proportional hazards regression model of time to death or dialysis (n = 205 patients)
Variable* Beta SE Hazard ratio 95% CI P value
Pre-EGFR –0.0368 0.0134 0.96 0.94, 0.99 .006
EGFR–no change 1.7918 0.5181 6.00 2.17, 16.57 .001
IA–no change –0.0565 0.0229 — — .014
EGFR–worse 0.7998 0.3613 2.23 1.10, 4.52 .027
History–DM 0.6959 0.2667 2.01 1.19, 3.38 .009
*All variables significant at less than .10 have been included.
DM, Diabetes mellitus; EGFR, estimated glomerular filtration rate (in mL/min · m2); IA, term for interaction.
blood pressure measurements and medication
requirements at least 8 weeks after surgery, as previ-
ously described.16 Of the 215 patients surviving sur-
gical repair, 11% were considered cured, 76% were
considered improved, and 13% were considered
failed. Blood pressure response among patients with
ischemic nephropathy was not associated with either
mortality from all causes (Fig 2, A) or cardiovascu-
lar mortality (Fig 2, B) on follow-up.
Renal function response
Renal function response was determined from
EGFR as estimated from SCr as measured at least 3
weeks after surgery. A significant change in renal
function was defined as a change of 20% or more in
EGFR or removal from dialysis dependence.
Of 215 surgical survivors, 58% had improved
renal function, 35% were considered to have func-
tion that was unchanged, and 7% were considered to
have function that was worsened after surgical repair.
Twenty-seven patients (75%) who had been dialysis-
dependent before surgery were removed permanent-
ly from dialysis after surgery. All surgical survivors
being considered, there was a significant difference
between preoperative EGFR and postoperative
EGFR (23 ± .7 mL/min · m2 and 31.7 ± 1.1
mL/min · m2, respectively; P = .0001).
Table IV summarizes the influence of site of dis-
ease and extent of surgical repair on recovery of
renal function. Repair of both unilateral and bilater-
al renal artery disease was associated with a statisti-
cally significant increase in postoperative EGFR.
However, bilateral renal artery repair was associated
with a significantly greater mean incremental
increase in EGFR in comparison with unilateral
repair (11.0 ± 1.3 vs 6.9 ± 1.7 mL/min · m2; P =
.001). Bilateral repair of significant disease to two
kidneys led to the greatest mean increase in EGFR.
Among preoperative parameters, men (men, 54%
improvement; women, 68% improvement; P = .037)
and patients with diabetes (diabetics, 51% improve-
ment; nondiabetics, 60% improvement; P = .032)
demonstrated a decreased rate of improved renal
function after surgical repair.
Table V relates preoperative SCr and dialysis
dependence to postoperative renal function. As the
preoperative SCr increased or renal function pro-
gressed to dialysis dependence, a greater proportion
of patients demonstrated a 20% or more increase in
EGFR. In those patients with the most severely
impaired preoperative renal function, 75% were
removed from dialysis dependence. This association
between increased preoperative SCr and improved
postoperative EGFR was significant (P = .01).
In contrast to what was seen with hypertension
response, there were strong and independent rela-
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Table IV. Change in EGFR by site of disease and extent of operation (n = 215 patients)
Preoperative EGFR Postoperative EGFR (mean ± SE)
N (mean ± SE) Unadjusted Adjusted
Unilateral 78 26.79 ± 1.26 ← P < .001 → 33.70 ± 1.65 31.17 ± 1.67
↑ ↑
P = .001 P = .210
↓ ↓
Bilateral 137 21.23 ± .94 ← P < .001 → 32.38 ± 1.51 33.83 ± 1.25
Two kidneys* 97 20.53 ± 1.11 ← P < .001 → 33.40 ± 1.11 —
Uni/neph† 24 22.45 ± 2.16 ← P < .001 → 28.16 ± 2.70 —
Solitary‡ 16 23.68 ± 3.08 ← P < .001 → 32.62 ± 3.08 —
*Renal artery repair to two kidneys.
†Renal artery repair with contralateral nephrectomy.
‡Renal artery repair to solitary kidney.
Table V. Renal function response vs preoperative SCr
Preoperative SCr
Renal function response* 1.8-2.9 mg/dL ≥ 3.0 mg/dL Dialysis-dependent Total (%)
Improved (%) 52 59 75 58
No change (%) 39 33 25 35
Worse (%) 9 8 — 7
*See text for definition.
tionships between renal function response and clini-
cal outcome. Tables III and VI summarize the mul-
tivariate analysis for time to death or dialysis depen-
dence and dialysis dependence alone. Compared
with surgical survivors with improved renal function
after surgery, patients who were unchanged and
patients whose function was worsened demonstrated
an increased risk of eventual dialysis dependence and
death or dialysis that was highly significant and inde-
pendent of other factors. For time to death or dialy-
sis, a significant interaction between preoperative
EGFR and unchanged renal function was observed
(Fig 1 and Table III). For time to dialysis, significant
interactions between preoperative EGFR and both
unchanged and worsened renal function were
observed (Table VI).
The product-limit estimates of dialysis-free sur-
vival according to postoperative renal function
response are depicted in Fig 3.
DISCUSSION
In the absence of criteria that accurately predict
recovery of renal function, do the results from opera-
tion described in this experience support surgical
intervention for ischemic nephropathy? A 7.3% peri-
operative mortality was observed. On mean follow-up
of 38 months, 72 additional patients (33%) died or
progressed to dialysis dependence. Patients who expe-
rienced incremental improvement in early excretory
renal function demonstrated improved dialysis-free
survival during follow-up, but only when compared
with patients with unchanged or worsened function
after operation. In the absence of a randomly selected
comparative group managed medically without oper-
ation, this essential question remains unanswered.
Unfortunately, few data are available regarding
the mortality or dialysis risk associated with untreat-
ed atherosclerotic renal artery disease, with or with-
out renal insufficiency. Conlon et al17 reported on
all-cause mortality among patients chosen for cardiac
catheterization studied simultaneously with abdomi-
nal aortography.18 In this group, 15% of 1235
patients demonstrated at least one renal artery with 
≥ 50% diameter-reducing stenosis. Among patients
with renovascular disease, the 4-year estimated sur-
vival was 65%—significantly decreased in comparison
with that for age- and sex-matched controls without
renal artery stenosis. As determined by means of
multivariate analysis, significant and independent
predictors of mortality included the presence of renal
artery disease, an elevated SCr level, and decreased
left ventricular performance. Given these indepen-
dent relationships among anatomic renal artery dis-
ease, elevated SCr level, and follow-up mortality, the
poor survival observed in our patients unimproved
after surgical treatment may approximate the expect-
ed mortality of patients with ischemic nephropathy
managed medically without intervention.
This notion is supported by Baboolac et al,19
who reported on the mortality and dialysis risk of
patients with renal artery disease managed without
intervention. Over an 8-year period, these authors
retrospectively identified 51 patients with angio-
graphic evidence of bilateral renovascular disease (ie,
≥ 90% diameter-reducing renal artery stenosis, with
at least 50% contralateral stenosis). Each of these
patients had received medical treatment, but none
had received renal artery intervention. By product-
limit estimates, 40% of these patients died within 2
years of diagnosis and the progression to dialysis
dependence was 35% at 5 years. All of these obser-
vations correlate closely with the estimates of death
and dialysis dependence in our patients with
unchanged renal function after surgery.
Surprisingly few reports on ischemic nephropathy
relate function response after renal artery interven-
tion to clinically relevant end-points—eventual dialy-
sis dependence or death. Chaikof et al20 described
renal function response, survival, and dialysis-free
survival in 50 patients with ischemic nephropathy
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Table VI. Proportional hazards regression model of time to dialysis (n = 196 patients)
Variable* Beta SE Hazard ratio 95% CI P value
Pre-EGFR –0.0266 0.0218 0.97 0.93, 1.02 .223
EGFR–no change 3.0294 0.7634 20.69 4.63, 92.36 > .001
IA–no change –0.119 0.0356 — — .001
EGFR–worse 4.348 1.6055 77.33 3.32, 1798.67 .007
IA–worse 0.1335 0.0703 — — .058
Age –0.0446 0.0226 0.96 0.92, 1.00 .049
CEA 1.0494 0.4018 2.86 1.30, 6.28 .009
Male –0.654 0.321 0.52 0.27, 0.99 .048
*All variables significant at less than .10 have been included.
CEA, Carotid endarterectomy; EGFR, estimated glomerular filtration rate (mL/min · m2); IA, term for  interaction.
treated surgically with combined aortic and renal
reconstruction. Patients who reached dialysis depen-
dence and death on postoperative follow-up had
failed to demonstrate improved renal function after
operative intervention. Although follow-up dialysis
dependence demonstrated a significant univariate
association with postoperative EGFR that was
unchanged or worsened, the relationship between
function response and survival or dialysis-free survival
was not statistically significant.
Despite the absence of prospective data, clinical
experience suggests that ischemic nephropathy can
mediate a rapid decline in renal function. The rate of
decline in function has been recently described for a
patient subgroup characterized by a preoperative
SCr level of at least 1.8 mg/dL with at least three
measures of renal function before and after
surgery.16 Among patients with ischemic nephropa-
thy proved by an immediate increase in renal func-
tion after surgery, the preoperative decline in EGFR
exceeded 5% per week. Immediate improvement in
renal function was also associated with a significant
decrease in the rate of decline in postoperative
EGFR. Conversely, patients with renal function
unimproved after operation continued to decline in
EGFR at a rate that was unchanged. These observa-
tions correlate with the relationship between renal
function response and clinical outcome described in
this report. Only patients with an incremental
increase in EGFR after operation demonstrated
improved dialysis-free survival on follow-up.
This relationship between early renal function
response and dialysis-free survival has important
implications. First, the method of intervention for
ischemic nephropathy should be selected that pro-
vides maximal retrieval of renal function. This selec-
tion should consider the pattern of atherosclerotic
disease typically found in this patient population.2 In
our experience, ostial atherosclerosis accounted for
97% of renal artery stenosis, 32% of renal artery dis-
ease was represented by complete occlusion, and
64% of patients had bilateral renal artery stenosis or
occlusion. Second, clinical benefit after renal artery
intervention probably applies only to those patients
who demonstrate an incremental increase in excre-
tory renal function. Consequently, the common
practice of considering patients with unchanged
renal function to be “preserved” or “stable” should
be abandoned. Patients with unimproved renal func-
tion are not “preserved”; rather, they remain at high
risk for both dialysis dependence and death.11 Given
the significant interaction between preoperative
EGFR and death or eventual dialysis dependence for
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patients who are unchanged, this issue has greatest
importance for patients with severe preoperative
renal insufficiency (see Fig 1).
The primary aim of this retrospective review was
to examine the relationship between renal function
response and dialysis-free survival. Although we
believe that this analysis provides important informa-
tion relative to the issue, bias inherent in our patient
selection limits the general application of these obser-
vations. All consecutive patients with atherosclerotic
renovascular disease and ischemic nephropathy were
included for analysis. However, patients were select-
ed for intervention on the basis of severe hyperten-
sion in combination with severe (≥ 80% diameter-
reducing stenosis or occlusion), surgically correctable
renal artery lesions. Patients with mild hypertension
and moderate renovascular disease in combination
with renal insufficiency were excluded from surgical
intervention.2,16 Moreover, patients with advanced
renal insufficiency and dialysis-dependent ischemic
nephropathy were most commonly chosen for inter-
vention when the decline in renal function preceding
surgery had been rapid and severe occlusive disease
was present to the entire renal mass.16,21 The poten-
tial influence of this selection bias was most obvious
among patients with severe preoperative renal insuf-
ficiency. Other authors have suggested that a marked
elevation in SCr precludes meaningful recovery of
renal function.3,5,6 On the contrary, when surgical
intervention was guided by the selection criteria
described above rather than by the absolute value of
preoperative SCr, increased SCr was associated with
an increased probability of improved postoperative
renal function (Table V).
In addition to this selection bias, a few features of
our surgical strategy deserve comment. The greatest
incremental increase in EGFR occurred with simulta-
neous correction of all significant renovascular dis-
ease. As a result, complete renal revascularization was
attempted at a single operation in every patient.2 Our
experience with renal artery occlusion has demon-
strated potential recovery of renal function regardless
of kidney size, angiographic evidence of collateraliza-
tion, or reconstitution of the distal renal artery.22
Consequently, each renal artery occlusion was
explored in anticipation of repair. Nephrectomy was
reserved for an unreconstructable renal artery to a
kidney providing less than 10% to 20% of overall
function by preoperative renography. Finally, a signif-
icant and independent relationship between failed
surgical repair and eventual dialysis dependence has
been demonstrated.23 Renal artery repairs were
examined with intraoperative duplex sonography
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scanning to minimize these postoperative failures.24
Major B-scan defects were revised before the com-
pletion of surgery, providing an estimated primary
patency rate of 97% at 5 years.23
The lack of association between hypertension
response and estimated survival among patients with
ischemic nephropathy deserves special comment.
This observation does not agree with surgical results
among patients with renovascular hypertension
managed decades earlier. In this latter patient group,
Dean et al25 reported that beneficial blood pressure
response (ie, cured or improved hypertension) was
associated with a significant increase in estimated
survival in comparison with a failed response.25
There are several potential explanations of why our
experience with ischemic nephropathy was different.
First, the average length of follow-up for our
patients with ischemic nephropathy was significantly
shorter (3.3 years vs 17 years). Second, the average
patient in this series was significantly older at the
point of surgical intervention (66 years vs 50 years),
and there was a significantly greater prevalence of
extrarenal atherosclerosis (87% vs 40%). Finally, and
probably most importantly, each patient in this
review was selected on the basis of preoperative
excretory renal insufficiency; in contrast, renal insuf-
ficiency was present in only 7% of patients previous-
ly reported. The strong independent effects of
increased patient age and preoperative renal dys-
function may obscure any survival benefit conferred
by a beneficial blood pressure response in the con-
temporary patient group with ischemic nephropathy.
In summary, surgical repair of renovascular dis-
ease can retrieve significant excretory renal function
in selected patients with severe hypertension and
ischemic nephropathy. Early renal function response
appears to exert important effects on time to dialysis
dependence and dialysis-free survival. Specifically,
patients with improved renal function after surgery
demonstrated freedom from dialysis dependence
and improved dialysis-free survival that was signifi-
cant and independent in comparison with patients
whose renal function was unchanged or worsened.
Most important, these results provide further sup-
port for a carefully controlled, prospective, random-
ized trial comparing operative renal artery repair,
PTA, and medical management to confirm or refute
the value of renal artery intervention in patients with
ischemic nephropathy.
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DISCUSSION
Dr Elliot Chaikof (Atlanta, Ga). Members and guests.
The careful, methodical, and insightful study of patients
with atherosclerotic renovascular disease is a well estab-
lished tradition at Wake Forest University, and it is a fore-
gone conclusion that the vascular surgical community has
come to expect periodic guidance and well-reasoned
advice from Richard Dean and Kim Hansen. I have little
doubt that today’s report on the surgical management of
patients with ischemic nephropathy will be considered a
citation classic in the field. 
In this review, Cherr, Hansen, and colleagues have
updated their institutional experience that now encom-
passes 232 patients treated over a 12-year period. All
these patients suffered from hypertension and diminished
excretory renal function, and all were managed following
an established practice of aggressive surgical salvage for
the failing kidney. There are few other institutions in this
country or abroad that approach the depth of experience
and expertise harbored by this group, and their results
may well be considered the gold standard for surgical
therapy. Thus, it is particularly sobering that well over
40% of their patients exhibit either diminished or no
improvement in renal function after surgical intervention.
Traditionally, vascular surgeons have reasoned that
patients who have not incurred a measured improvement
in postoperative renal function nonetheless have been
beneficiaries of surgical intervention because of anticipat-
ed preservation of the threatened kidney. The data
reported from the Wake Forest group, which support ear-
lier observations from our own division at Emory, ques-
tion this assumption and suggest that this population
remains at significant risk in the near term for both death
and dialysis. To put the Wake Forest data in their starkest
terms, within 3 years of surgery, one in every three
patients had either died or progressed to dialysis. So is the
glass half empty or half full? Improving organ perfusion
makes common sense, and it seems an appropriate
assumption that at least some of those patients who
progress to dialysis dependence would probably have
done so within a shorter time frame if surgery had not
been offered. Therefore, would it not be reasonable to
conclude that aggressive surgical intervention should be
accepted as dictum since it provides a beneficial effect in
at least 60% of patients, even if the results are somewhat
clouded in the remainder?
Unfortunately, life is not that simple. Despite inter-
vention in a recognized center of excellence, surgical
revascularization at Wake Forest University was associated
with serious perioperative morbidity in 30% of patients
and a 30-day mortality of 7.3%. The national statistics,
particularly in low-volume centers, are likely to be signifi-
cantly worse. Thus, the upfront cost for surgery is quite
high. Simply put, there are not many operative procedures
in common use today in which the costs are so high and
the outcome so unclear in such a significant proportion of
patients. There is no doubt that we should continue work-
ing as we have during the past three decades toward devel-
oping discriminant tests that predict a positive response to
revascularization and adjunctive measures that improve
the functional response to surgery or reduce its associated
morbidity. However, I am not aware of any new measures
or tests that are poised to enter the clinic. Therefore, given
the low morbidity and mortality associated with renal
artery angioplasty and stenting, there exists a critical need
to define the population, which is best served by surgery
and that which is ideally managed using an endovascular
route. Common sense is not always a universal truth. I
would like to pose three questions.
I suspect that the authors have performed a power
analysis in considering the design of a randomized trial for
evaluating outcome following surgery, angioplasty, or
medical management. We all agree that such a trial is nec-
essary, but can the authors comment on its feasibility?
Given the sobering data presented in this report, do the
authors intend to change their criteria for referring
patients with ischemic nephropathy for either angioplasty
and stenting or medical care alone? And could the authors
identify any relationship between intraoperative renal
ischemia time and outcome?
I would like to thank the society for the privilege of
discussing this fine report.
Dr Gregory Cherr. Thank you, Dr Chaikof, for your
insightful comments and questions.
We are very excited about the prospects for a prospec-
tive randomized trial to compare medical therapy, percu-
taneous therapy, and open surgical revascularization. We
base our calculations on 80% power, assuming that there
will be 10% incidence of events per year. With those cal-
culations we would need 70 patients per group. We antic-
ipate three groups: one group receiving the best medical
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therapy, one group receiving the best medical therapy plus
angioplasty and/or stenting, and a third group receiving
the best medical therapy and surgery. If our intervention-
al radiologists are able to dilate occluded renal arteries, we
would anticipate accruing 210 patients over a 3-year peri-
od. If our radiologists are not able to dilate occluded renal
arteries, we would need two more groups: one with
patients with occluded renal arteries receiving the best
medical therapy and another with patients with occluded
renal arteries receiving the best medical therapy and
surgery. In this case we would require 350 patients for the
five groups accrued over 5 years.
Your second question regarded referral for treatment
of patients with ischemic nephropathy. During your ques-
tion you correctly noted that this is a sobering disease. I
think that it is very important to recognize that athero-
sclerotic renal artery stenosis carries a poor prognosis,
regardless of therapy. 
The patients we operated on for ischemic nephropathy
are highly selected. They are all extremely hypertensive.
They all have increased serum creatinines. Two thirds of
them have bilateral renal artery disease, and most of them
were referred to us for ischemic nephropathy, not
aneurysms or aortoiliac occlusive disease. Without a
prospective randomized trial, we can only compare our
patients with those described in other papers. 
First I will talk about medical therapy. A recent study
from Duke by Conlon looked at 1235 patients who were
undergoing cardiac catheterization. While pulling out
angiogram catheters, the authors did aortograms. Fifteen
percent of the patients had renal artery disease, which they
treated with medical therapy alone. They then prospectively
followed those patients over 4 years and found that their sur-
vival was 67%, significantly worse than patients without renal
artery disease. By multivariate analysis, renal artery disease
and elevated creatinine were both associated with death.
We were able to remove 75% of the dialysis-dependent
patients from dialysis after surgery. Patients with ischemic
nephropathy who require dialysis have a dismal prognosis.
When Mailloux looked at a series of patients beginning
dialysis and stratified them based on cause of renal failure,
the patients who had ischemic nephropathy did the worst.
Their 5-year survival was 12%. We surmise that our sub-
group of patients, who were dialysis dependent, had an
extremely poor prognosis without an operation. Because
we were able to remove three quarters of those patients
from dialysis dependence, we feel that surgery was of great
benefit to these patients. 
Next, I will mention angioplasty and stenting. Two of
the vascular fellows preceding me at Wake Forest, Dr Tim
Oskin and Dr James Wong, reviewed the world literature
from 1991 to 1999, looking specifically for patients who
had stenting done for ostial stenosis. They found 350
patients in whom they could quantify the postprocedure
renal function response. They found that only 15% of
patients had an improved renal function response compared
with 60% of the patients in our group. Again, we feel that
we offer more of a benefit to patients with surgery than, as
best as we can tell, patients get from renal artery stenting. 
The 7% mortality associated with operation for ischemic
nephropathy is important to note when considering treat-
ment options for this patient population. But, because we
feel that can help a large majority of these patients with
surgery, we do not plan to change our referral pattern.
Your last question was in regard to intraoperative renal
ischemia time. During this study we did not look at renal
ischemia time, but we have examined it in a previous
study. We looked at approximately 150 patients and found
no relationship between intraoperative renal ischemia time
and renal function response and long-term outcome. 
Dr Jacob Robison (Mount Pleasant, SC). Your group
has previously indicated that not only is the absolute value
of the creatinine important, but maybe the time course of
the deterioration may also be important. I wonder if you
could tell us how that factored into your analysis.
Secondly, this seems like it would be ideally suited to
decision analysis as a tool to determine quality-adjusted
life years and see whether such effort is really worth it in
the long run. I wonder if you might comment.
Thank you very much.
Dr Cherr. As part of the selection process for surgery, we
consider the rate of decline of renal function. Specifically, we
feel that patients with a rapidly rising serum creatinine have
a better chance of deriving benefit from surgery. We do not
usually offer renal artery surgery to patients with an elevat-
ed creatinine that is stable or has been rising slowly.
Quality-adjusted life years are important concepts to
consider in this patient population.
